View in EDS

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.

Saved in:
Bibliographic Details
Title: Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
Authors: Douma LH; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Noort V; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Lalezari F; Department of Radiology; Netherlands Cancer Institute, Amsterdam, Netherlands., de Vries JF; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Monkhorst K; Department of Pathology; Netherlands Cancer Institute, Amsterdam, Netherlands., Smesseim I; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Baas P; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Schilder B; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Vermeulen M; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Burgers JA; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: s.burgers@nki.nl., de Gooijer CJ; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Dec; Vol. 26 (12), pp. 1676-1684.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41308680
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Douma+LH%22">Douma LH</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Noort+V%22">van der Noort V</searchLink>; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Lalezari+F%22">Lalezari F</searchLink>; Department of Radiology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Vries+JF%22">de Vries JF</searchLink>; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Monkhorst+K%22">Monkhorst K</searchLink>; Department of Pathology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Smesseim+I%22">Smesseim I</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Baas+P%22">Baas P</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schilder+B%22">Schilder B</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Vermeulen+M%22">Vermeulen M</searchLink>; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Burgers+JA%22">Burgers JA</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: s.burgers@nki.nl.<br /><searchLink fieldCode="AU" term="%22de+Gooijer+CJ%22">de Gooijer CJ</searchLink>; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Dec; Vol. 26 (12), pp. 1676-1684.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41308680
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(25)00514-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1676
    Titles:
      – TitleFull: Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Douma LH
      – PersonEntity:
          Name:
            NameFull: van der Noort V
      – PersonEntity:
          Name:
            NameFull: Lalezari F
      – PersonEntity:
          Name:
            NameFull: de Vries JF
      – PersonEntity:
          Name:
            NameFull: Monkhorst K
      – PersonEntity:
          Name:
            NameFull: Smesseim I
      – PersonEntity:
          Name:
            NameFull: Baas P
      – PersonEntity:
          Name:
            NameFull: Schilder B
      – PersonEntity:
          Name:
            NameFull: Vermeulen M
      – PersonEntity:
          Name:
            NameFull: Burgers JA
      – PersonEntity:
          Name:
            NameFull: de Gooijer CJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1